Local and national advocacy support

Ralph S. Shapiro, Marcia Boyle, Elena E. Perez

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient's experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.

Original languageEnglish
JournalJournal of Clinical Immunology
Volume32
Issue numberSUPPL. 2
DOIs
StatePublished - Jul 19 2012

Fingerprint

Organizations
Immunoglobulin G
Health Insurance Reimbursement
Physicians
Allergy and Immunology
Hypersensitivity
Therapeutics
Asthma

Keywords

  • AAAAI IGIV toolkit
  • Immune Deficiency Foundation
  • Jeffrey Modell Foundation
  • Primary immunodeficiency disease
  • Treatment guidelines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Local and national advocacy support. / Shapiro, Ralph S.; Boyle, Marcia; Perez, Elena E.

In: Journal of Clinical Immunology, Vol. 32, No. SUPPL. 2, 19.07.2012.

Research output: Contribution to journalArticle

Shapiro, Ralph S. ; Boyle, Marcia ; Perez, Elena E. / Local and national advocacy support. In: Journal of Clinical Immunology. 2012 ; Vol. 32, No. SUPPL. 2.
@article{db3f7582695b4c368518f01ac5c65182,
title = "Local and national advocacy support",
abstract = "Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient's experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.",
keywords = "AAAAI IGIV toolkit, Immune Deficiency Foundation, Jeffrey Modell Foundation, Primary immunodeficiency disease, Treatment guidelines",
author = "Shapiro, {Ralph S.} and Marcia Boyle and Perez, {Elena E.}",
year = "2012",
month = "7",
day = "19",
doi = "10.1007/s10875-012-9736-6",
language = "English",
volume = "32",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Local and national advocacy support

AU - Shapiro, Ralph S.

AU - Boyle, Marcia

AU - Perez, Elena E.

PY - 2012/7/19

Y1 - 2012/7/19

N2 - Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient's experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.

AB - Decisions by third-party payors that are restricting delivery of appropriate IgG treatment for primary immunodeficiency disease (PIDD) are summoning action from patients, physicians, and their organizations to ensure that high quality treatment remains accessible. Some of the strongest advocacy to date is from patient organizations, such as the Immune Deficiency Foundation (IDF), which strive to educate stakeholders on key issues that determine patient access to appropriate IgG treatment. These issues include the ability to choose the appropriate site of care based on a patient's experience and circumstance and greater awareness of product choice. Advocacy by physicians on these issues at the local level is needed, as are national efforts by organizations such as the American Academy of Allergy, Asthma & Immunology and their regional societies.

KW - AAAAI IGIV toolkit

KW - Immune Deficiency Foundation

KW - Jeffrey Modell Foundation

KW - Primary immunodeficiency disease

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=84874403891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874403891&partnerID=8YFLogxK

U2 - 10.1007/s10875-012-9736-6

DO - 10.1007/s10875-012-9736-6

M3 - Article

VL - 32

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - SUPPL. 2

ER -